Transgene and NEC Corporation announced that new data have been presented on TG4050, an individualized neoantigen cancer vaccine, at the American Society of Clinical Oncology Annual Meeting in Chicago, IL. TG4050 is based on Transgene’s myvac® platform and powered by NEC’s cutting-edge AI capabilities.
